Weight-Loss Meds Like Wegovy Could Battle Alcoholism
Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds. People taking this class of drugs, called glucagon-like peptide-1 receptor agonists (GLP-1),
Judge Karen Marston held that, despite plaintiffs' arguments to the contrary, marketing discovery is not relevant to the ...
New research estimates that expanded access to Ozempic and similar drugs could lead to 42,000 deaths prevented annually.
Since 2021, the Obesity Action Coalition (OAC) has led a national public awareness campaign against weight bias with a goal ...
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
Only 15% of those who start a glucagon-like peptide 1 (GLP-1) for weight loss are still taking it two years according to ...
Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...
Eli Lilly (NYSE:LLY) has partnered with the British government to launch a first-of-its-kind real-world study to evaluate the ...
Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.
A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...
Revolutionary weight management and diabetes medications could prove to be the next frontier in addiction recovery treatment medications.
Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...
Hosted on MSN22h
Lilly Loses Around $14B This Week: How to Play LLY StockThe stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback